NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET

7.1 GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Pfizer Inc.

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 GlaxoSmithKline plc

16.3 Boehringer Ingelheim International GmbH

16.4 Johnson & Johnson Services, Inc.

16.5 Bayer AG

16.6 AstraZeneca

16.7 Zyla Life Sciences

16.8 Horizon Therapeutics plc

16.9 Reckitt Benckiser Group plc

16.10 Novartis International AG

16.11 Daiichi Sankyo Company, Limited.

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER